| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 09/02/2004 | US20040171066 Template-fixed peptidomimetics with antimicrobial activity |
| 09/02/2004 | US20040171064 Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| 09/02/2004 | US20040171056 Using peptide nucleic acids to identify genic variations which enhance gene therapeutic and/or drug treatments |
| 09/02/2004 | US20040171042 Functional assays that use theT1R1 receptor to screen for T1R1-associated taste modulators |
| 09/02/2004 | US20040171037 Using genic copy number of oncogenes to diagnose, prevent and treat tumor disorders; antitumor agents |
| 09/02/2004 | US20040171024 Comprises nucleotide sequences coding multidrug resistance proteins for transformation, propagation and generating cells for use as tools in screening insecticides |
| 09/02/2004 | US20040171020 Glanders/meliodosis vaccines |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040171015 Cyp450-specific dna probes and primers, and biological applications thereof |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040171009 Lipid-associated molecules |
| 09/02/2004 | US20040171008 G-protein coupled receptor arrays |
| 09/02/2004 | US20040171005 Codon-optimised nucleic acid coding for apoaequorin and uses thereof |
| 09/02/2004 | US20040171003 Using oligonucleotide probes to generate gene expression profile of tumor marker proteins for use in diagnosis of cell proliferative disorders |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170998 Identifying modulators which effect post-transcriptional intron removal from partially processed messenger RNA; screening for fungicides and/or bactericides; enzyme inhibitors |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170994 DNA sequences for human tumour suppressor genes |
| 09/02/2004 | US20040170993 Methods for diagnosing and treating heart disease |
| 09/02/2004 | US20040170992 Diagnostic polymorphisms of tgf-beta1 promoter |
| 09/02/2004 | US20040170987 Polynucleotides encoding polypeptides involved in intermediates metabolism of central metabolic pathway in methylophilus methylotrophus |
| 09/02/2004 | US20040170986 Polynucleotides encoding polypeptides involved in amino acid biosynthesis in methylophilus methylotrophus |
| 09/02/2004 | US20040170985 Polynucleotides encoding polypeptides involved in the stress response to environmental changes in methylophilus methylotrophus |
| 09/02/2004 | US20040170982 Novel therapeutic targets in cancer |
| 09/02/2004 | US20040170976 for drug screening expression libraries for microbiocides; solid phase synthesis; genetic engineering |
| 09/02/2004 | US20040170975 alternative splicing variant of tumor necrosis factor receptor (TNFR); for detection assays; solid phase synthesis; genetic engineering |
| 09/02/2004 | US20040170972 comprises DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine; includes use of serological diagnosis; genetic engineering |
| 09/02/2004 | US20040170971 kits for detecting amplification or elevated expression for diagnosis; genetic engineering; solid phase synthesis |
| 09/02/2004 | US20040170970 Split- ubiquitin based reporter systems and methods of their use |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170967 Assays for detection of bacillus anthracis |
| 09/02/2004 | US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits |
| 09/02/2004 | US20040170960 Lectin compositions and methods for modulating an immune response to an antigen |
| 09/02/2004 | US20040170956 Method for identifying targeting domains and methods and compositions comprising the same |
| 09/02/2004 | US20040170955 Human and mouse targeting peptides identified by phage display |
| 09/02/2004 | US20040170951 Nucleotide sequences of the nucleocapsid (NP) and phosphoprotein (P) genes of a malaysian velogenic newcastle disease virus strain AF2240 and the production of the NP and P proteins in Escherichia coli |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170651 In vivo modulation of neuronal transport |
| 09/02/2004 | US20040170647 Recombinant adenovirus vaccines |
| 09/02/2004 | US20040170644 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 09/02/2004 | US20040170643 heat shock protein fused to a single epitope-containing segment comprising two or more identical epitopes and a DNA construct encoding it; reducing levels of a predetermined protein (e.g., hormone(s)) in an animal; vaccines |
| 09/02/2004 | US20040170641 Prevention and treatment of amyloidogenic disease |
| 09/02/2004 | US20040170636 DNA vaccine comprising a plasmid vector encoding the A2 gene from Leishmania donovani; vector may also encode a gene, such as the Human papillomavirus E6 gene, capable of mediating degradation of the cellular protein p53, to inhibit the p53 response |
| 09/02/2004 | US20040170635 administering an inhibitor of the CD2/LFA-3 interaction, in combination with narrow band UVB radiation; especially for treating psoriasis |
| 09/02/2004 | US20040170622 Methods and compositions for modulating XBP-1 activity |
| 09/02/2004 | US20040170621 inhibiting eosinophil chemotactic factor-L expression or activity by means including use of anti-ECF-L antibody, antisense S-oligonucleotide to ECF-L, mECF-L polyclonal antisera, rabbit preimmune antisera, OPG RANK-Fc or by inhibiting osteoclast formation; also administering mECF-L with RANKL |
| 09/02/2004 | US20040170616 transferring a gene to preselected vertebrate cells by accelerating microprojectiles carrying polynucleic acid sequences having a regulatory sequence in the 5' to 3' direction and a gene downstream from the sequence at the cells to penetrate them and deposit the polynucleic acid sequences therein. |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170607 Reducing viability of tumor cells by administering a virus; differential sensitivity using interferons |
| 09/02/2004 | US20040170605 Activation gene expression of slug gene; transplant or gene therapy; sexual disorders; fertility |
| 09/02/2004 | US20040170604 Genetic engineering; yeast culture product; blood platelet proliferative agents |
| 09/02/2004 | US20040170602 Dominant negative proteins and methods thereof |
| 09/02/2004 | US20040170598 Polysubstituted polycarboxylic phosphoamide biopolymers, methods for their production and uses of compositions derived therefrom |
| 09/02/2004 | DE10248141A1 Nukleinsäuren und deren Verwendung für die Gentherapie Nucleic acids and their use for gene therapy |
| 09/02/2004 | CA2843744A1 Delta-endotoxin genes and methods for their use |
| 09/02/2004 | CA2824150A1 Expression of class 2 mannosidase and class iii mannosidase in lower eukaryotic cells |
| 09/02/2004 | CA2787820A1 Glycoprotein antigen sima135 expressed in metastatic human tumor cells |
| 09/02/2004 | CA2753408A1 Production of modified glycoproteins having multiple antennary structures |
| 09/02/2004 | CA2714863A1 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
| 09/02/2004 | CA2556785A1 Coating composition for polymeric surfaces comprising serpin or serpin derivatives |
| 09/02/2004 | CA2516971A1 Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof |
| 09/02/2004 | CA2516550A1 Production of modified glycoproteins having multiple antennary structures |
| 09/02/2004 | CA2516520A1 N-acetylglucosaminyltransferase iii expression in lower eukaryotes |
| 09/02/2004 | CA2516486A1 Method of treating ischemic disease |
| 09/02/2004 | CA2516371A1 Method of diagnosis of type 2 diabetes and early onset thereof |
| 09/02/2004 | CA2516366A1 Glycorpotein antigen sima135 expressed in metastatic human tumor cells |
| 09/02/2004 | CA2516349A1 Delta-endotoxin genes and methods for their use |
| 09/02/2004 | CA2516293A1 Fusion proteins of interferon alpha muteins with improved properties |
| 09/02/2004 | CA2516284A1 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
| 09/02/2004 | CA2516282A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 09/02/2004 | CA2516138A1 Therapeutic gpcr targets in cancer |
| 09/02/2004 | CA2516128A1 Therapeutic targets in cancer |
| 09/02/2004 | CA2515965A1 Inhibition of tace or amphiregulin for the modulation of egf receptor signal transactivation |
| 09/02/2004 | CA2515948A1 Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof |
| 09/02/2004 | CA2515515A1 Mtor kinase-associated proteins |
| 09/02/2004 | CA2514979A1 Antibody vaccine conjugates and uses therefor |
| 09/02/2004 | CA2514342A1 Water soluble animal muscle protein product |
| 09/02/2004 | CA2513307A1 Analogues of glp-1 |
| 09/02/2004 | CA2511855A1 Use of caspase enzymes for maturation of engineered recombinant polypeptide fusions |
| 09/02/2004 | CA2498650A1 Mycobacterial diagnostics |
| 09/01/2004 | EP1452600A1 Receptor and nucleic acid molecule encoding said receptor |
| 09/01/2004 | EP1452599A1 Improved epitope displaying phage |
| 09/01/2004 | EP1452596A1 Environmental stress-responsive promoters and genes encoding transcriptional factor |
| 09/01/2004 | EP1452593A1 Dna synthesis promoters, dna polymerase-associated factors and utilization thereof |
| 09/01/2004 | EP1452592A1 Rice transposon genes |
| 09/01/2004 | EP1452591A1 Fluorescent protein |
| 09/01/2004 | EP1452589A1 ADP-ribosyltransferase c3cer |
| 09/01/2004 | EP1452543A2 RGD (ARG-GLY-ASP) coupled to (neuro)peptides |
| 09/01/2004 | EP1452542A2 Reshaped human monoclonal antibodies specific for IgE |
| 09/01/2004 | EP1452541A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 09/01/2004 | EP1452540A2 Molecular sequence of swine retrovirus and methods of use |
| 09/01/2004 | EP1452539A1 Antifreeze proteins originating in fishes |
| 09/01/2004 | EP1452538A1 Method of manufacturing T-20 and T-1249 peptides at commercial scale, and T-20 and T-1249 compositions related thereto |
| 09/01/2004 | EP1452183A1 Use of PGRP, LRRP and CTL proteins to trigger an anti-Plasmodium immune response in Anopheles species |
| 09/01/2004 | EP1452093A1 Chimeric nonhuman animal |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451581A2 Toll-like receptor 3 signaling agonists and antagonists |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451576A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 09/01/2004 | EP1451552A2 Reagents and methods useful for detecting diseases of the breast |